S1P receptor modulators in cell trafficking and therapeutics

Current Immunology Reviews

Volumn 8, Issue 2, 2012, Pages 170-180

  Gonzalez Cabrera, Pedro J ^a   Cahalan, Stuart M ^a   Ferguson, Jill ^a   Rosen, Hugh ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Chemical agonist; Drug selectivity; FTY720; GPCR; Lymphopenia; S1P

Indexed keywords

3 [2 (3 TRIFLUOROMETHYL 4 BIPHENYLYL)BENZO[B]THIEN 5 YLMETHYLAMINO]PROPIONIC ACID; CD19 ANTIGEN; CD8 ANTIGEN; CHEMOKINE RECEPTOR CCR7; FINGOLIMOD; G PROTEIN COUPLED RECEPTOR; HERMES ANTIGEN; MESSENGER RNA; PADGEM PROTEIN; SPHINGOSINE 1 PHOSPHATE RECEPTOR;

APOPTOSIS; AUTOIMMUNE DISEASE; B LYMPHOCYTE; BINDING AFFINITY; BIOTRANSFORMATION; BONE MARROW CELL; BONE MARROW TRANSPLANTATION; CATALYSIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INTERACTION; COMPETITIVE INHIBITION; DENDRITIC CELL; DOSE RESPONSE; DRUG EFFICACY; ENANTIOMER; ENDOTHELIUM CELL; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HYDROPHOBICITY; IMMUNOCOMPETENT CELL; IMMUNOCYTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE FUNCTION; LYMPHOCYTOPENIA; MEMORY CELL; MULTIPLE SCLEROSIS; NERVE CELL; NONHUMAN; OLIGODENDROGLIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 84860271398     PISSN: 15733955     EISSN: 1875631X     Source Type: Journal    
DOI: 10.2174/157339512800099710     Document Type: Review

References (58)

1. Adachi K, Kohara T, Nakao N, et al. Design, synthesis, and structureactivity- relationships of 2-substituted-2-amino-1,3-propanediols - discovery of a novel immunosuppressant, FTY720. Bioorg Med Chem Lett 1995; 5(8): 853-856.
2. Chiba K, Hoshino Y, Suzuki C, et al. FTY720, a novel immunosuppressant possessing unique mechanisms 1. Prolongation of skin allograft survival and synergistic effect in combination with cyclosporine in rats. Transplant Proc 1996; 28(2): 1056-1059.
3. Hoshino Y, Suzuki C, Ohtsuki M, et al. FTY720, a novel immunosuppressant possessing unique mechanisms 2. Long-term graft survival induction in rat heterotopic cardiac allografts and synergistic effect in combination with cyclosporine A. Transplant Proc 1996; 28(2): 1060-1061.
4. Masubuchi Y, Kawaguchi T, Ohtsuki M, et al. FTY720, a novel immunosuppressant, possessing unique mechanisms 4. Prevention of graft versus host reactions in rats. Transplant Proc 1996; 28(2): 1064-1065.
5. Mandala S, Hajdu R, Bergstrom J, et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science, 2002; 296(5566): 346-349.
6. Kiuchi M, Adachi K, Kohara T, et al. Synthesis and biological evaluation of 2,2-disubstituted 2-aminoethanols: analogues of FTY720. Bioorg Med Chem Lett 1998; 8(1): 101-106.
7. Gonzalez-Cabrera PJ, Hla T, and Rosen H. Mapping pathways downstream of sphingosine 1-phosphate subtype 1 by differential chemical perturbation and proteomics. J Biol Chem 2007; 282(10): 7254-7264.
8. Rosen H, Alfonso C, Surh CD, et al. Rapid induction of medullary thymocyte phenotypic maturation and egress inhibition by nanomolar sphingosine 1-phosphate receptor agonist. Proc Natl Acad Sci USA 2003; 100(19): 10907-12.
9. Sanna MG, Liao J, Jo E, et al. Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate. J Biol Chem 2004; 279(14): 13839-48.
10. Niessen F, Schaffner F, Furlan-Freguia C, et al. Dendritic cell PAR1- S1P3 signalling couples coagulation and inflammation. Nature 2008; 452(7187): 654-658.
11. Sanchez T, Estrada-Hernandez T, Paik JH, et al. Phosphorylation and action of the immunomodulator FTY720 inhibits vascular endothelial cell growth factor-induced vascular permeability. J Biol Chem 2003; 278(47): 47281-47290.
12. Pan S, Mi Y, Pally C, et al. A monoselective sphingosine-1-phosphate receptor-1 agonist prevents allograft rejection in a stringent rat heart transplantation model. Chem Biol 2006; 13(11): 1227-34.
13. Schurer SC, Brown SJ, Gonzales Cabrera PJ, et al. Ligand-Binding Pocket Shape Differences between Sphingosine 1-Phosphate (S1P) Receptors S1P1 and S1P3 Determine Efficiency of Chemical Probe Identification by Ultrahigh-Throughput Screening. ACS Chem Biol 2008; 3(8): 486-498.
14. Deng Q, Clemas JA, Chrebet G, et al. Identification of Leu276 of the S1P1 receptor and Phe263 of the S1P3 receptor in interaction with receptor specific agonists by molecular modeling, site-directed mutagenesis, and affinity studies. Mol Pharmacol 2007; 71(3): 724-735.
15. Sanna MG, Wang SK, Gonzalez-Cabrera PJ, et al. Enhancement of capillary leakage and restoration of lymphocyte egress by a chiral S1P1 antagonist in vivo. Nat Chem Biol 2006; 2(8): 434-441.
16. Davis MD, Clemens JJ, Macdonald TL, et al. Sphingosine 1-phosphate analogs as receptor antagonists. J Biol Chem 2005; 280(11): 9833-9841.
17. Gonzalez-Cabrera PJ, Jo E, Sanna MG, et al. Full pharmacological efficacy of a novel S1P1 agonist that does not require S1P-like headgroup interactions. Mol Pharmacol 2008; 74(5): 1308-1318.
18. Matloubian M, Lo CG, Cinamon G, et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 2004; 427(6972): 355-360.
19. Halin C, Scimone ML, Bonasio R, et al. The S1P-analog FTY720 differentially modulates T-cell homing via HEV: T-cell-expressed S1P1 amplifies integrin activation in peripheral lymph nodes but not in Peyer patches. Blood 2005; 106(4): 1314-1322.
20. Rosen H, Gonzalez-Cabrera PJ, Sanna MG, et al. Sphingosine 1- phosphate receptor signaling. Annu Rev Biochem 2009; 78: 743-768.
21. Schwab SR and Cyster JG. Finding a way out: lymphocyte egress from lymphoid organs. Nat Immunol 2007; 8(12): 1295-301.
22. Don AS, Martinez-Lamenca C, Webb WR, et al. Essential requirement for sphingosine kinase 2 in a sphingolipid apoptosis pathway activated by FTY720 analogues. J Biol Chem 2007; 282(21): 15833-15842.
23. Hait NC, Allegood J, Maceyka M, et al. Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate. Science 2009; 325(5945): 1254-1257.
24. Allende ML, Sasaki T, Kawai H, et al. Mice deficient in sphingosine kinase 1 are rendered lymphopenic by FTY720. J Biol Chem 2004; 279(50): 52487-52492.
25. Mechtcheriakova D, Wlachos A, Sobanov J, et al. FTY720-phosphate is dephosphorylated by lipid phosphate phosphatase 3. FEBS Lett 2007; 581(16): 3063-3068.
26. Yamanaka M, Anada Y, Igarashi Y, et al. A splicing isoform of LPP1, LPP1a, exhibits high phosphatase activity toward FTY720 phosphate. Biochem Biophys Res Commun 2008; 375(4): 675-679.
27. Payne SG, Oskeritzian CA, Griffiths R, et al. The immunosuppressant drug FTY720 inhibits cytosolic phospholipase A2 independently of sphingosine-1-phosphate receptors. Blood 2007; 109(3): 1077-1085.
28. Bandhuvula P, Tam YY, Oskouian B, et al. The immune modulator FTY720 inhibits sphingosine-1-phosphate lyase activity. J Biol Chem 2005; 280(40): 33697-33700.
29. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362(5): 402-415.
30. Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010; 362(5): 387-401.
31. Brinkmann V. FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system. Br J Pharmacol 2009; 158(5): 1173-1182.
32. Hofmann M, Brinkmann V, and Zerwes HG. FTY720 preferentially depletes naive T cells from peripheral and lymphoid organs. Int Immunopharmacol 2006; 6(13/14): 1902-1910.
33. LaMontagne K, Littlewood-Evans A, Schnell C, et al. Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization. Cancer Res 2006; 66(1): 221-231.
34. Li HS, Meno-Tetang GML, Chiba KJ, et al. Pharmacokinetics and cell trafficking dynamics of 2-amino-2-[2-(4-octylphenyl)ethyl]propane- 1,3-diol hydrochloride (FTY720) in cynomolgus monkeys after single oral and intravenous doses. J Pharmacol Exp Ther, 2002; 301(2): 519-526.
35. Maeda Y, Matsuyuki H, Shimano K, et al. Migration of CD4 T cells and dendritic cells toward sphingosine 1-phosphate (S1P) is mediated by different receptor subtypes: S1P regulates the functions of murine mature dendritic cells via S1P receptor type 3. J Immunol 2007; 178(6): 3437-3446.
36. Mehling M, Brinkmann V, Antel J, et al. FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis. Neurology 2008; 71(16): 1261-1267.
37. Metzler B, Gfeller P, Wieczorek G, et al. Modulation of T cell homeostasis and alloreactivity under continuous FTY720 exposure. Int Immunol 2008; 20(5): 633-644.
38. Miron VE, Jung CG, Kim HJ, et al. FTY720 modulates human oligodendrocyte progenitor process extension and survival. Ann Neurol 2008; 63(1): 61-71.
39. Morris MA, Gibb DR, Picard F, et al. Transient T cell accumulation in lymph nodes and sustained lymphopenia in mice treated with FTY720. Eur J Immunol 2005; 35(12): 3570-3580.
40. Niessen F, Furlan-Freguia C, Fernandez JA, et al. Endogenous EPCR/aPC-PAR1 signaling prevents inflammation-induced vascular leakage and lethality. Blood 2009; 113(12): 2859-2866.
41. Novgorodov AS, El-Alwani M, Bielawski J, et al. Activation of sphingosine-1-phosphate receptor S1P5 inhibits oligodendrocyte progenitor migration. FASEB J 2007; 21(7): 1503-1514.
42. Pham TC, Fells JI, Sr., Osborne DA, et al. Molecular recognition in the sphingosine 1-phosphate receptor family. J Mol Graph Model 2008; 26(8): 1189-1201.
43. Yagi H, Kamba R, Chiba K, et al. Immunosuppressant FTY720 inhibits thymocyte emigration. Eur J Immunol 2000; 30(5): 1435-1444.
44. Zhang ZY, Zhang Z, and Schluesener HJ. FTY720 attenuates lesional interleukin-17(+) cell accumulation in rat experimental autoimmune neuritis. Neuropathol Appl Neurobiol 2009; 35(5): 487-495.
45. Honig SM, Fu S, Mao X, et al. FTY720 stimulates multidrug transporter- and cysteinyl leukotriene-dependent T cell chemotaxis to lymph nodes. J Clin Invest 2003; 111(5): 627-637.
46. Yopp AC, Fu S, Honig SM, et al. FTY720-enhanced T cell homing is dependent on CCR2, CCR5, CCR7, and CXCR4: evidence for distinct chemokine compartments. J Immunol 2004; 173(2): 855-865.
47. Cinamon G, Matloubian M, Lesneski MJ, et al. Sphingosine 1- phosphate receptor 1 promotes B cell localization in the splenic marginal zone. Nat Immunol 2004; 5(7): 713-720.
48. Cinamon G, Zachariah MA, Lam OM, et al. Follicular shuttling of marginal zone B cells facilitates antigen transport. Nat Immunol 2008; 9(1): 54-62.
49. Graler MH and Goetzl EJ. The immunosuppressant FTY720 downregulates sphingosine 1-phosphate G-protein-coupled receptors. FASEB J 2004; 18(3): 551-553.
50. Oo ML, Thangada S, Wu MT, et al. Immunosuppressive and antiangiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor. J Biol Chem 2007; 282(12): 9082-9089.
51. Jo E, Sanna MG, Gonzalez-Cabrera PJ, et al. S1P1-selective in vivoactive agonists from high-throughput screening: off-the-shelf chemical probes of receptor interactions, signaling, and fate. Chem Biol 2005; 12(6): 703-715.
52. Foss FW, Jr., Snyder AH, Davis MD, et al. Synthesis and biological evaluation of gamma-aminophosphonates as potent, subtype-selective sphingosine 1-phosphate receptor agonists and antagonists. Bioorg Med Chem 2007; 15(2): 663-677.
53. Wei SH, Rosen H, Matheu MP, et al. Sphingosine 1-phosphate type 1 receptor agonism inhibits transendothelial migration of medullary T cells to lymphatic sinuses. Nat Immunol 2005; 6(12): 1228-1235.
54. Cahalan SM, Gonzalez-Cabrera PJ, Sarkisyan G, et al. Differential mechanisms revealed by short duration S1P1 agonism using fluorescence-tagged S1P1 knock-in mice. Nat Chem Biol 2011; [In Press].
55. Brinkmann V, Billich A, Baumruker T, et al. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov, 2010; 9(11): 883-897.
56. Choi JW, Gardell SE, Herr DR, et al. FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1- phosphate receptor 1 (S1P1) modulation. Proc Natl Acad Sci U S A 2011; 108(2): 751-756.
57. Foster CA, Howard LM, Schweitzer A, et al. Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis. J Pharmacol Exp Ther 2007; 323(2): 469-475.
58. Mattes H, Dev KK, Bouhelal R, et al. Design and synthesis of selective and potent orally active S1P5 agonists. ChemMedChem 2010; 5(10): 1693-1696.